Program
OTS-412
A development code.
Its studies are led by Bionoxx.
Furthest: phase 1, since Jul 30, 20253 company-led studies, 2 open or runningNext primary completion: Dec 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bionoxx | 32 open or running | phase 1since Jul 30, 2025 | Jul 30, 2025 | Dec 2028phase 1 · NCT07190833 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 30, 2025First study: phase 1 study in Treatment-Refractory Solid TumorsFirst studyNCT07170592 · 24 planned
- Sep 17, 2025Phase 1 study in Treatment-Refractory Solid TumorsNCT07190833 · 21 planned · South Korea
- Nov 16, 2025Early phase 1 study in Healthy VolunteerNCT07302945 · 1 enrolled · South Korea
Ahead
- Dec 2028Primary completion: phase 1 study in Treatment-Refractory Solid TumorsNCT07190833
- Dec 2028Primary completion: phase 1 study in Treatment-Refractory Solid TumorsNCT07170592
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07302945Healthy Volunteer · South Korea | Early 1 | Completed | Jan 14, 2022 | 1 |
| NCT07190833Treatment-Refractory Solid Tumors · South Korea | 1 | Recruiting | Dec 2028 | 21 |
| NCT07170592Treatment-Refractory Solid Tumors | 1 | Not yet recruiting | Dec 2028 | 24 |
How it is read
Names in the registry
- “OTS-412”, 8 entries
Codes read as this program: OTS412.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.